Samsung Biologics Statistics
Total Valuation
KRX:207940 has a market cap or net worth of KRW 73.67 trillion. The enterprise value is 73.82 trillion.
Market Cap | 73.67T |
Enterprise Value | 73.82T |
Important Dates
The last earnings date was Wednesday, April 23, 2025.
Earnings Date | Apr 23, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
KRX:207940 has 71.17 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 71.17M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.01% |
Owned by Institutions (%) | 14.13% |
Float | 18.07M |
Valuation Ratios
The trailing PE ratio is 68.00 and the forward PE ratio is 55.40. KRX:207940's PEG ratio is 2.89.
PE Ratio | 68.00 |
Forward PE | 55.40 |
PS Ratio | 16.20 |
PB Ratio | 6.76 |
P/TBV Ratio | 9.29 |
P/FCF Ratio | 207.11 |
P/OCF Ratio | 44.40 |
PEG Ratio | 2.89 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 38.41, with an EV/FCF ratio of 207.54.
EV / Earnings | 68.14 |
EV / Sales | 16.23 |
EV / EBITDA | 38.41 |
EV / EBIT | 55.81 |
EV / FCF | 207.54 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.14.
Current Ratio | 1.43 |
Quick Ratio | 0.35 |
Debt / Equity | 0.14 |
Debt / EBITDA | 0.77 |
Debt / FCF | 4.18 |
Interest Coverage | 26.37 |
Financial Efficiency
Return on equity (ROE) is 10.45% and return on invested capital (ROIC) is 6.84%.
Return on Equity (ROE) | 10.45% |
Return on Assets (ROA) | 4.94% |
Return on Invested Capital (ROIC) | 6.84% |
Return on Capital Employed (ROCE) | 9.79% |
Revenue Per Employee | 953.32M |
Profits Per Employee | 227.11M |
Employee Count | 4,770 |
Asset Turnover | 0.27 |
Inventory Turnover | 0.83 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.41% in the last 52 weeks. The beta is 0.43, so KRX:207940's price volatility has been lower than the market average.
Beta (5Y) | 0.43 |
52-Week Price Change | +32.41% |
50-Day Moving Average | 1,084.00 |
200-Day Moving Average | 1,000.00 |
Relative Strength Index (RSI) | 46.49 |
Average Volume (20 Days) | 85,060 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:207940 had revenue of KRW 4.55 trillion and earned 1.08 trillion in profits. Earnings per share was 15,220.67.
Revenue | 4.55T |
Gross Profit | 2.27T |
Operating Income | 1.32T |
Pretax Income | 1.37T |
Net Income | 1.08T |
EBITDA | 1.92T |
EBIT | 1.32T |
Earnings Per Share (EPS) | 15,220.67 |
Balance Sheet
The company has 1.33 trillion in cash and 1.49 trillion in debt, giving a net cash position of -154.95 billion or -2,177.07 per share.
Cash & Cash Equivalents | 1.33T |
Total Debt | 1.49T |
Net Cash | -154.95B |
Net Cash Per Share | -2,177.07 |
Equity (Book Value) | 10.90T |
Book Value Per Share | 153,211.51 |
Working Capital | 1.66T |
Cash Flow
In the last 12 months, operating cash flow was 1.66 trillion and capital expenditures -1,303.57 billion, giving a free cash flow of 355.68 billion.
Operating Cash Flow | 1.66T |
Capital Expenditures | -1,303.57B |
Free Cash Flow | 355.68B |
FCF Per Share | 4,997.36 |
Margins
Gross margin is 50.01%, with operating and profit margins of 29.03% and 23.82%.
Gross Margin | 50.01% |
Operating Margin | 29.03% |
Pretax Margin | 30.13% |
Profit Margin | 23.82% |
EBITDA Margin | 42.20% |
EBIT Margin | 29.03% |
FCF Margin | 7.82% |
Dividends & Yields
KRX:207940 does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 1.47% |
FCF Yield | 0.48% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
KRX:207940 has an Altman Z-Score of 6.83.
Altman Z-Score | 6.83 |
Piotroski F-Score | n/a |